3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
Cisplatin
72
Brachytherapy
31
Radiotherapy
26
Paclitaxel
23
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
21
human papillomavirus vaccine, L1 type 16, 18
20
Topotecan
18
Papillomavirus Vaccines
18
Carboplatin
18
Surveys and Questionnaires
17
Bevacizumab
16
pembrolizumab
14
Radiation
12
Gemcitabine
12
Early Intervention, Educational
12
Colposcopy
12
Methods
11
Magnetic Resonance Spectroscopy
11
atezolizumab
10
Radiotherapy, Intensity-Modulated
10
Blood Specimen Collection
10
Papanicolaou Test
9
Docetaxel
9
Vaccines, Synthetic
8
Platinum
8
Nivolumab
8
Ipilimumab
8
Counseling
8
1,2-diaminocyclohexaneplatinum II citrate
8
Vaccines
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Uterine Cervical Neoplasms
×
nanocis
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled